AXS-05 is a novel, oral, investigational NMDA receptor antagonist
with multimodal activity.
Considering the fact that magnesium acts as a physiological NMDA receptor antagonist
, thus potentially preventing excessive glutamatergic transmission, while also blocking the increase in NO production, the aim of the present study was to evaluate the effect of magnesium sulfate on thermal hyperalgesia in rats exposed to repeated forced swim stress.
Some studies have shown antidepressant effects of Ketamine (NMDA receptor antagonist
) but, it is also known psychedelic and dissociative drug.
'As a selective NMDA receptor antagonist
, ketamine seems to be binding to a subreceptor that's responsible for the symptoms that patients with these syndromes experience.
Table 1 Formulations of naltrexone Brand Generic Release Formulation ReVia Naltrexone IR Tablet Vivitrol Naltrexone ER Powder for suspension Brand Available Tmax Half life doses ReVia 50 mg 1 hour Parent: 4 hours Metabolite: 14 hours Vivitrol 380 mg First peak: 5 to 10 days 2 hours after injection Second peak: 2 to 3 days after injection Source: Reference 1 IR: immediate release; ER: extended release; Tmax: time to peak concentration Table 2 Nonopioid options for managing procedural pain Nonopioid Notes Ketamine Noncompetitive NMDA receptor antagonist
Amantadine, a NMDA receptor antagonist
, has been widely studied in patients with traumatic brain injury (TBI), and its efficacy on neurocognitive improvement after TBI has been demonstrated (6-10).
Quoin's two lead products are expected to be different applications of a single NMDA receptor antagonist
Moreover, we aimed to show ketamine, an NMDA receptor antagonist
, and caffeine, a modulator of intracellular calcium, interaction with the antiepileptic effects of opipramol in the PTZ-induced seizures.
Early Use of the NMDA Receptor Antagonist
Ketamine in Refractory and Superrefractory Status Epilepticus.
Zeiler, "Early Use of the NMDA Receptor Antagonist
Ketamine in Refractory and Superrefractory Status Epilepticus," Critical Care Research and Practice, vol.
There have been several reports on the antidyskinetic effects of amantadine, a nonselective NMDA receptor antagonist
.[sup],, Amantadine has been approved for the treatment of LID despite its side effects such as confusion, constipation, and visual hallucinations.
MK801 (Sigma Chemical, St Louis, MO, USA; 0.01, 0.1, 1 [micro]M), a NMDA receptor antagonist
; NS398 (1, 10, and 100 [micro]M), a COX-2 selective inhibitor; DKK-1 (R&D Systems; 10, 50, 100ng/ml), a Wnt/[beta]-catenin signaling inhibitor; and bevacizumab (0.25, 2.5, and 25mg/ml), an anti-VEGF antibody were intravitreally injected with the 80 nmol NMDA in some rats.